Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be HIV positive who must have received less than 7 days total of any antiretroviral therapy (HIV related therapy)~Extension Studies:~* First extension: Patient completed the 48-week base study~* Second extension: Patient completed the first 144-week extension study~Exclusion Criteria:~* Less than 18 years of age~* Individuals who currently do not test positive for HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 600 mg monotherapy (Type: EXPERIMENTAL): MK0518 600 mg twice daily
- 400 mg monotherapy (Type: EXPERIMENTAL): MK0518 400 mg twice daily
- 200 mg monotherapy (Type: EXPERIMENTAL): MK0518 200 mg twice daily
- 100 mg monotherapy (Type: EXPERIMENTAL): MK0518 100 mg twice daily
- placebo monotherapy (Type: PLACEBO_COMPARATOR): Placebo to MK0518 twice daily
- 600 mg combo therapy (Type: EXPERIMENTAL): MK0518 600 mg + tenofovir + lamivudine
- 400 mg combo therapy (Type: EXPERIMENTAL): MK0518 400 mg + tenofovir + lamivudine
- 200 mg combo therapy (Type: EXPERIMENTAL): MK0518 200 mg + tenofovir + lamivudine
- 100 mg combo therapy (Type: EXPERIMENTAL): MK0518 100 mg + tenofovir + lamivudine
- EFV combo therapy (Type: ACTIVE_COMPARATOR): efavirenz + tenofovir + lamivudine

Based on this trial design, predict the completion outcome and termination type (if applicable).